Co-Radiotherapy with Tyrosine Kinase Inhibitors Might Benefit Survival in Hepatoma Patients with Portal Vein Tumor Thrombosis.

IF 4.4 3区医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY

Biomedical Journal Pub Date : 2025-08-13 DOI:10.1016/j.bj.2025.100904

Hui-Ling Huang, Wei-Ming Lin, Chia-Hsuan Lai, Te-Sheng Chang, Sheng-Nan Lu

{"title":"Co-Radiotherapy with Tyrosine Kinase Inhibitors Might Benefit Survival in Hepatoma Patients with Portal Vein Tumor Thrombosis.","authors":"Hui-Ling Huang, Wei-Ming Lin, Chia-Hsuan Lai, Te-Sheng Chang, Sheng-Nan Lu","doi":"10.1016/j.bj.2025.100904","DOIUrl":null,"url":null,"abstract":"Background: Hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) is associated with a poor prognosis, and current treatment options yield suboptimal results. This article aims to share our treatment outcomes for PVTT using tyrosine kinase inhibitors (TKIs), radiation therapy (RT), and their combination.Methods: From 2010 to 2021, a total of 160 Child-Pugh class A HCC patients with PVTT, but without extrahepatic spread, were enrolled. Among them, 26, 10, 81, and 43 patients underwent no treatment, RT, TKIs, and combination therapy, respectively.Results: Compared to the no treatment group (median survival: 2 months), the RT group (4.5 months, p=0.034), TKIs group (5.0 months, p=0.0017), and combination group (15.0 months, p<0.001) all demonstrated a survival benefit. The multivariate Cox model showed adjusted hazard ratios and 95% confidence intervals of 0.35 (0.16-0.78), 0.40 (0.25-0.63) and 0.26 (0.15-0.44) for RT, TKIs, combination groups, respectively. From clinical observation of patients who survived for two years, we found that 20% of RT patients achieved good local control, and the RT group had longer durations of TKI use.Conclusions: In this series, 26.9% (43/160) of HCC patients with PVTT underwent combination treatment with TKIs and RT, achieving a median survival of 15.0 months. The contributions of RT were 20% disease control rate and may extend the duration of TKIs use. Therefore, all candidates without contraindications should be considered for combination treatment.","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":" ","pages":"100904"},"PeriodicalIF":4.4000,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.bj.2025.100904","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) is associated with a poor prognosis, and current treatment options yield suboptimal results. This article aims to share our treatment outcomes for PVTT using tyrosine kinase inhibitors (TKIs), radiation therapy (RT), and their combination.

Methods: From 2010 to 2021, a total of 160 Child-Pugh class A HCC patients with PVTT, but without extrahepatic spread, were enrolled. Among them, 26, 10, 81, and 43 patients underwent no treatment, RT, TKIs, and combination therapy, respectively.

Results: Compared to the no treatment group (median survival: 2 months), the RT group (4.5 months, p=0.034), TKIs group (5.0 months, p=0.0017), and combination group (15.0 months, p<0.001) all demonstrated a survival benefit. The multivariate Cox model showed adjusted hazard ratios and 95% confidence intervals of 0.35 (0.16-0.78), 0.40 (0.25-0.63) and 0.26 (0.15-0.44) for RT, TKIs, combination groups, respectively. From clinical observation of patients who survived for two years, we found that 20% of RT patients achieved good local control, and the RT group had longer durations of TKI use.

Conclusions: In this series, 26.9% (43/160) of HCC patients with PVTT underwent combination treatment with TKIs and RT, achieving a median survival of 15.0 months. The contributions of RT were 20% disease control rate and may extend the duration of TKIs use. Therefore, all candidates without contraindications should be considered for combination treatment.

查看原文本刊更多论文

酪氨酸激酶抑制剂联合放疗可能有利于肝癌门静脉肿瘤血栓患者的生存。

背景：肝细胞癌（HCC）合并门静脉肿瘤血栓（PVTT）预后不良，目前的治疗方案效果不佳。本文旨在分享我们使用酪氨酸激酶抑制剂（TKIs）、放射治疗（RT）及其联合治疗PVTT的治疗结果。方法：2010 - 2021年共纳入160例Child-Pugh a级HCC合并PVTT但无肝外扩散患者。其中26例、10例、81例和43例患者分别接受了不治疗、RT、TKIs和联合治疗。结果：与未治疗组（中位生存期为2个月）相比，RT组（中位生存期为4.5个月，p=0.034）、TKIs组（中位生存期为5.0个月，p=0.0017）和联合治疗组（中位生存期为15.0个月）。结论：在本研究中，26.9%（43/160）的HCC PVTT患者接受了TKIs和RT联合治疗，中位生存期为15.0个月。RT对疾病控制率的贡献为20%，并可能延长TKIs的使用时间。因此，所有无禁忌症的候选药物应考虑联合治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomedical Journal Medicine-General Medicine

CiteScore

11.60

自引率

1.80%

发文量

128

审稿时长

42 days

期刊介绍： Biomedical Journal publishes 6 peer-reviewed issues per year in all fields of clinical and biomedical sciences for an internationally diverse authorship. Unlike most open access journals, which are free to readers but not authors, Biomedical Journal does not charge for subscription, submission, processing or publication of manuscripts, nor for color reproduction of photographs. Clinical studies, accounts of clinical trials, biomarker studies, and characterization of human pathogens are within the scope of the journal, as well as basic studies in model species such as Escherichia coli, Caenorhabditis elegans, Drosophila melanogaster, and Mus musculus revealing the function of molecules, cells, and tissues relevant for human health. However, articles on other species can be published if they contribute to our understanding of basic mechanisms of biology. A highly-cited international editorial board assures timely publication of manuscripts. Reviews on recent progress in biomedical sciences are commissioned by the editors.